Small-cell lung cancer detection in never-smokers: clinical characteristics and multigene mutation profiling using targeted next-generation sequencing-Reference-Cited by-同舟云学术

Small-cell lung cancer detection in never-smokers: clinical characteristics and multigene mutation profiling using targeted next-generation sequencing

Published:2015-01 Issue:1 Volume:26 Page:161-166
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Sun J.-M.,Choi Y.-L.,Ji J.H.,Ahn J.S.,Kim K.-M.,Han J.,Ahn M.-J.,Park K.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Reference20 articles.

1. Lung cancer in never smokers: clinical epidemiology and environmental risk factors;Samet;Clin Cancer Res,2009

2. Korean ethnicity as compared with white ethnicity is an independent favorable prognostic factor for overall survival in non-small cell lung cancer before and after the oral epidermal growth factor receptor tyrosine kinase inhibitor era;Ahn;J Thorac Oncol,2010

3. Never-smokers with lung cancer: epidemiologic evidence of a distinct disease entity;Toh;J Clin Oncol,2006

4. Incidence of lung cancer in a large cohort of non-smoking men from Sweden;Boffetta;Int J Cancer,2001

5. Lung cancer incidence in never smokers;Wakelee;J Clin Oncol,2007

Cited by 49 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Small cell lung cancer: emerging subtypes, signaling pathways, and therapeutic vulnerabilities;Experimental Hematology & Oncology;2024-08-05

2. Female Patients with Small Cell Lung Cancer Have Better Survival than Males with Extensive but Not Limited Disease;Oncology Research and Treatment;2024-07-22

3. Tislelizumab Plus Platinum and Etoposide Versus Placebo Plus Platinum and Etoposide as First-Line Treatment for Extensive-Stage SCLC (RATIONALE-312): A Multicenter, Double-Blind, Placebo-Controlled, Randomized, Phase 3 Clinical Trial;Journal of Thoracic Oncology;2024-07

4. Unusual response with tyrosine kinase inhibitor in small-cell lung cancer;Annals of Oncology Research and Therapy;2024-07

5. The Evolving Scenario of ES-SCLC Management: From Biology to New Cancer Therapeutics;Genes;2024-05-27